HUMA vs. RCUS, LENZ, ZYME, VALN, SYRE, MLYS, STOK, NUVB, VERV, and PRAX
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Arcus Biosciences (RCUS), LENZ Therapeutics (LENZ), Zymeworks (ZYME), Valneva (VALN), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Stoke Therapeutics (STOK), Nuvation Bio (NUVB), Verve Therapeutics (VERV), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.
Humacyte vs. Its Competitors
Arcus Biosciences (NYSE:RCUS) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.
92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 5.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Humacyte has a net margin of 0.00% compared to Arcus Biosciences' net margin of -109.56%. Humacyte's return on equity of 0.00% beat Arcus Biosciences' return on equity.
In the previous week, Arcus Biosciences and Arcus Biosciences both had 5 articles in the media. Arcus Biosciences' average media sentiment score of 1.44 beat Humacyte's score of -0.28 indicating that Arcus Biosciences is being referred to more favorably in the media.
Humacyte has lower revenue, but higher earnings than Arcus Biosciences. Humacyte is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
Arcus Biosciences presently has a consensus target price of $21.14, indicating a potential upside of 99.18%. Humacyte has a consensus target price of $9.75, indicating a potential upside of 517.09%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Arcus Biosciences.
Arcus Biosciences has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.
Summary
Humacyte beats Arcus Biosciences on 10 of the 15 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
This page (NASDAQ:HUMA) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access